Wellnex Life (ASX:WNX) announced it has received market authorisation from the Therapeutic Goods Administration for its liquid paracetamol plus caffeine soft gel product.
This addition expands the company's extensive range of authorised soft gel products.
The company's portfolio now includes four TGA-approved liquid soft gels, namely Liquid Paracetamol, Liquid Paracetamol plus Ibuprofen, Liquid Mini-Ibuprofen, and the newly introduced Liquid Paracetamol plus Caffeine.
The expansion demonstrates Wellnex Life's commitment to rapid product development in the consumer health market.
"The approval of liquid paracetamol plus caffeine soft gel market authorisation is a great testament to the company and its internal capabilities. This unique product will provide opportunities not only to use in the company's own brands but also opportunities to license it to third parties," said Zack Bozinovski, Managing Director of Wellnex Life.
The company's approved products are key assets for both Wellnex Life and affiliated national and international businesses like Chemist Warehouse and Haleon.
Wellnex Life's strategic licensing arrangements highlight its influence and reach in the global health sector.
Wellnex Life's achievements underscore its dedication to pioneering innovative health solutions and its growing footprint in both domestic and global markets.
At the time of reporting, Wellnex Life's share price was $0.68.